Therapy News and Research

RSS

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its supplemental Biologics License Application (sBLA) for SIMPONI.

25 Jul 2011

Circumcision prevents HIV transmission & cocktail of anti-HIV drugs prolong life

Reports came in last Wednesday that circumcision reduces transmission of HIV, in regions where transmission is high. To researchers, this procedure proves to be a cost-effective way to handle the pandemic. In South Africa, a study reported that men with circumcisions reduced new HIV infections by 76%.

24 Jul 2011

Researchers examine benefits of hyperbaric oxygen in treatment of aggressive brain cancer

In a unique study, researchers at The Long Island Brain Tumor Center at Neurological Surgery, P.C. are examining whether hyperbaric oxygen therapy - breathing pure oxygen while in a pressurized chamber - may prove a useful addition to the current standard of care for patients newly diagnosed with glioblastoma, an aggressive brain cancer.

22 Jul 2011

CDR recommends reimbursement for schizophrenia drug, ABILIFY

Bristol-Myers Squibb Canada is pleased to announce that the Common Drug Review (CDR) has recognized the value of ABILIFY® (aripiprazole) for the treatment of schizophrenia and schizoaffective disorders by recommending it be reimbursed by provincial drug plans for patients who have a contraindication to less-expensive antipsychotic agents or who have failed a trial of less expensive antipsychotic agents due to intolerance or lack of response.

22 Jul 2011

Comprehensive and age-appropriate evaluation during hospital stay is best for older patients

Older people rushed to the emergency room are more likely to be living at home up to a year later if they receive a comprehensive and age-appropriate evaluation during their hospital stay.

22 Jul 2011

Elite task force provides insights and guidance on deep brain stimulation for dystonia

Neurologist Michele Tagliati, MD, director of the Movement Disorders Program at Cedars-Sinai Medical Center, served on an elite international task force commissioned by the Movement Disorder Society to provide insights and guidance on deep brain stimulation for dystonia, an uncommon condition that causes sustained, sometimes crippling muscle contractions.

22 Jul 2011

Researchers dissociate beneficial and detrimental impacts of maternal regulatory T cells

A normal but concerning consequence of pregnancy is the fact that pregnant women are more susceptible to infection. University of Minnesota Medical School researchers have identified the underlying mechanisms for this physiologic immune suppression that may lead to new therapies to help ward off infections during pregnancy.

22 Jul 2011

Centric Health enters agreement to acquire majority stake in Performance Medical Group

Centric Health Corporation, Canada's leading diversified healthcare company, today announced that it has entered into an agreement to acquire 75% of the issued and outstanding securities of Performance Orthotics Inc., Footcare Dispensary Inc., and Foot Stress Inc..

22 Jul 2011

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Canadians newly diagnosed with a life-threatening blood cancer, chronic myeloid leukemia (CML) in chronic phase, now have a new treatment option available to them. Health Canada has granted a notice of compliance with conditions for SPRYCEL (dasatinib) as first-line treatment in patients with chronic phase CML.

22 Jul 2011

22nd Century receives FDA approval for X-22 IND to conduct Phase II-B smoking cessation trial

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) Application to conduct a Phase II-B clinical trial using X-22, a prescription smoking cessation aid in development.

22 Jul 2011

Impaired immunological memory causes psoriasis, atopic eczema

Scientists from the Centre for Allergy and Environment in Munich (ZAUM), the Helmholtz Zentrum München and the Technische Universität München have reached a milestone in their specialist area with their discovery of the causes of atopic eczema and psoriasis.

22 Jul 2011

Roche's cobas KRAS Mutation Test for colorectal cancer now available in Europe

Roche announced today that the cobas KRAS Mutation Test is now commercially available in Europe for use in colorectal cancer.

22 Jul 2011

FDA approves U.S. launch of Wiskott-Aldrich gene therapy clinical trial

The U.S. Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome.

22 Jul 2011

Study finds high prevalence of prescription pain medication addiction in chronic patients

A new study by Geisinger Health System researchers finds a high prevalence of prescription pain medication addiction among chronic pain patients.

22 Jul 2011

Quest receives U.S. patent allowance for cancer combination therapy

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has received notice of allowance for U.S. Patent Application 10/831,886 entitled: "Combination Therapy for Treating Disease".

22 Jul 2011

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of REMICADE for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.

22 Jul 2011

Sirtex reports 4Q sales growth of 23%

Sirtex Medical Limited (ASX:SRX) today said sales of SIR-Spheres® microspheres, it’s targeted radioactive treatment for inoperable liver cancer, grew 23% in the fourth quarter of the 2011 Financial Year compared with the same quarter last year. Full year dose sales grew 19.3% compared to a 14% growth the year before.

21 Jul 2011

Taller women more prone to cancer: Study

New research has shown that taller women could be more prone to suffering from cancer. The British study published online in the medical journal The Lancet on Thursday said cancer risk rose about 16% for every 4-inch rise in height. Increasing height heightened the chances of cancers of breast, ovary, womb, bowel, leukemia and malignant melanoma (skin cancer) the study found.

21 Jul 2011

High cost of multiple sclerosis drugs

According to a study released this Wednesday, drugs used in the hope of slowing multiple sclerosis progression may help some patients, but at a very high cost.

21 Jul 2011

Australian anti-cancer company completes $2.6 million placement

Australian monoclonal antibody company, Immune System Therapeutics Limited (IST), today said it completed a private placement to raise $2 million from new and existing private and institutional investors in Australia. Investors have agreed to purchase 5,200,000 shares in the company at a price of $0.50 cents per share resulting in gross proceeds of $2.6 million.

21 Jul 2011

Therapy News and Research

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

Circumcision prevents HIV transmission & cocktail of anti-HIV drugs prolong life

Researchers examine benefits of hyperbaric oxygen in treatment of aggressive brain cancer

CDR recommends reimbursement for schizophrenia drug, ABILIFY

Comprehensive and age-appropriate evaluation during hospital stay is best for older patients

Elite task force provides insights and guidance on deep brain stimulation for dystonia

Researchers dissociate beneficial and detrimental impacts of maternal regulatory T cells

Centric Health enters agreement to acquire majority stake in Performance Medical Group

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

22nd Century receives FDA approval for X-22 IND to conduct Phase II-B smoking cessation trial

Impaired immunological memory causes psoriasis, atopic eczema

Roche's cobas KRAS Mutation Test for colorectal cancer now available in Europe

FDA approves U.S. launch of Wiskott-Aldrich gene therapy clinical trial

Study finds high prevalence of prescription pain medication addiction in chronic patients

Quest receives U.S. patent allowance for cancer combination therapy

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Sirtex reports 4Q sales growth of 23%

Taller women more prone to cancer: Study

High cost of multiple sclerosis drugs

Australian anti-cancer company completes $2.6 million placement

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News